Anzeige
Mehr »
Login
Freitag, 27.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Insider-Alarm: Warum Insider Millionen von Aktien dieses Goldwerts kaufen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
269 Leser
Artikel bewerten:
(1)

ELISpot and FluoroSpot Assay Market worth $421 million | MarketsandMarkets

CHICAGO, Nov. 20, 2023 /PRNewswire/ -- ELISpot and FluoroSpot Assay Market in terms of revenue was estimated to be worth $ 292 million in 2023 and is poised to reach $ 421 million by 2028, growing at a CAGR of 7.6% from 2023 to 2028 according to a new report by MarketsandMarkets.

MarketsandMarkets_Logo

The growth of this market is majorly due to by Increasing use of ELISpot and FluoroSpot assays in the field of malignancy. However, Dearth of skilled professionals is one of the challenges for which may hinder the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584

Browse in-depth TOC on "ELISpot and FluoroSpot Assay Market"

207 - Tables
47 - Figures
232 - Pages

ELISpot and FluoroSpot Assay Market Scope:

Report Coverage

Details

Market Revenue in 2023

$292 million

Estimated Value by 2028

$421 million

Growth Rate

Poised to grow at a CAGR of 7.6%

Market Size Available for

2020-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Million)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product, Application, End User, and Region

Geographies Covered

North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World.

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Use Of Fluorospot Assays For Multiple-Analyte Detection In Single Well

Key Market Drivers

Increasing Incidence Of Chronic And Infectious Diseases And Growing Awareness About Early Disease Diagnosis

EliSpot Assay kits in the kits product segment to witness the highest shares during the forecast period.

Based on the product, Based on the product, the ELISpot and FluoroSpot Assays Market is classified into Assay Kits (By Technique - ELISpot Assay Kits, FluoroSpot Assay Kits., By Utility - Research Kits, Diagnostic Kits., By Analyte - T-cell-based Kits, B-cell-based Kits, Other Analyte Kits), Analyzers, Ancillary Products. The EliSpot Assay kits, segment is expected to dominate because of its wider application Assay kits typically offer a user-friendly and convenient solution for researchers and laboratories. They often come with pre-packaged reagents and standardized protocols, simplifying the assay process. Likewise, assay kits can be designed to cater to a wide range of users, from experienced researchers to those with less specialized expertise. This accessibility broadens the market and increases the adoption of EliSpot and FluoroSpot assays.

US dominates the North American ELISpot and FluoroSpot Assays Market

Based on the North America region, the ELISpot and FluoroSpot Assays Market is divided into US and Canada. US is expected to dominate the ELISpot and FluoroSpot Assays Market. The United States has a highly advanced and sophisticated healthcare infrastructure, including research facilities, laboratories, and healthcare institutions. This infrastructure supports the development, adoption, and implementation of advanced diagnostic technologies such as EliSpot and FluoroSpot assays. Similarly, The U.S. is a global hub for biomedical research and innovation. The presence of leading research institutions, academic centers, and biotechnology companies fosters a conducive environment for the development and validation of novel diagnostic as well as research assays.

China dominates the Asia Pacific ELISpot and FluoroSpot Assays Market

The APAC ELISpot and FluoroSpot Assays Market is segmented into Japan, China, India, and Rest of Apac. In 2023, China accounted for the largest share of the Asian ELISpot and FluoroSpot Assays Market. The large share of China can be attributed to the economic growth in the country, the increasing incidence of chronic diseases and the rising focus on vaccine development and cancer research, growth in the geriatric population, and favourable government support.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=124350584

ELISpot and FluoroSpot Assay Market Dynamics:

Drivers:

  • Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
  • Increasing vaccine development to address challenges of antimicrobial resistance
  • Increasing use of ELISpot and FluoroSpot assays in oncology
  • ELISpot assays as diagnostic tool in drug hypersensitivity reaction
  • Growth in biotechnology and biopharmaceutical industries

Restraints:

  • Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables
  • High cost of assays kits and analyzers

Opportunities:

  • Use of FluoroSpot assays for multiple-analyte detection in single well

Challenge:

  • Availability of alternative detection technologies
  • Dearth of skilled professionals

Key Market Players of ELISpot and FluoroSpot Assay Industry:

The major players in the ELISpot and FluoroSpot Assays Market are Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK), Becton, Dickinson and Company (BD) (US), Cellular Technology Limited (CTL) (US), Mabtech (Sweden), Abcam plc. (UK), Bio-Techne (US), Merck KGaA (Germany), Autoimmun Diagnostika GmbH (Germany), and U-CyTech (Netherland)

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=124350584

Recent Developments:

  • In 2022, The company Mabtech (Sweden) had made ELISpot kits available in a 100-plate format. Pre-coated plates are also included to save time and reduce assay variability. In 2022, The company also made available the Human IL-21 analyte in two colors in its FluoroSpot Flex platform.
  • In 2021, The company Cellular Technology Limited (CTL) (US) launched ImmunoSpot kits that contain precoating quality controlled (PCQC) plates, thereby adding an essential audit trail to ELISPOT analysis.

This report provides insights on the following pointers:

  • Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
  • Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market
  • Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

Related Reports:

Immunoassay Market - Global Forecasts to 2028

Point of Care Diagnostics Market - Global Forecasts to 2027

In Vitro Diagnostics Market - Global Forecasts to 2027

Infectious Disease Diagnostics Market - Global Forecasts to 2027

Immunofluorescence Assay Market - Global Forecasts to 2026

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/elispot-fluorospot-assay-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/elispot-fluorospot-assay.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/elispot-and-fluorospot-assay-market-worth-421-million--marketsandmarkets-301993277.html

© 2023 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.